- Home
- CYRX vs LXEO Comparison
CYRX vs LXEO Comparison
Compare CYRX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYRX | LXEO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 387.1M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CYRX | LXEO |
|---|---|---|
| Price | $14.77 | $5.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $13.31 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 816.2K | 753.5K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 39.81 |
| EPS | N/A | N/A |
| Revenue | ★ $176,177,000.00 | $654,000.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.69 | $3.60 |
| 52 Week High | $16.73 | $10.99 |
Technical Indicators
Market Signals| Indicator | CYRX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 51.12 |
| Support Level | $14.29 | $4.44 |
| Resistance Level | $16.73 | $6.26 |
| Average True Range (ATR) | 0.64 | 0.35 |
| MACD | -0.24 | 0.11 |
| Stochastic Oscillator | 14.52 | 69.47 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.